 <h1>Givosiran Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to givosiran: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, givosiran may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking givosiran:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain, severe</li>
<li>agitation</li>
<li>blood in the urine</li>
<li>coma</li>
<li>confusion</li>
<li>dark urine</li>
<li>decreased urine output</li>
<li>depression</li>
<li>dizziness</li>
<li>headache</li>
<li>irritability</li>
<li>lethargy</li>
<li>loss of appetite</li>
<li>muscle twitching</li>
<li>nausea or vomiting</li>
<li>rapid weight gain</li>
<li>seizures</li>
<li>stupor</li>
<li>swelling of the face, ankles, or hands</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Cough</li>
<li>difficulty swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>hives, itching, or skin rash</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>tightness in the chest</li>
<li>trouble breathing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of givosiran may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to givosiran: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions included nausea and injection site reactions.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylactic reaction, hypersensitivity</p><p>In clinical trials, 1 patient experienced an anaphylactic reaction and 1 patient experienced a hypersensitivity reaction.</p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Transaminase elevations (13%)</p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increase serum creatinine (15%; includes blood creatinine increased, glomerular filtration rate decreased, chronic kidney disease [decreased eGFR])</p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site reactions (25%)</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (27%)</p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (17%; includes pruritus, eczema, erythema, rash, pruritic rash, urticaria)</p><h3>Immunologic</h3><p>As with all oligonucleotides, there is a potential for immunogenicity.  The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and therefore comparison of antibody incidence is misleading.  In placebo-controlled and open-label clinical studies, 1 of 111 patients with acute hepatic porphyria (AHP;0.9%) developed treatment-emergent anti-drug antibodies (ADA) during treatment.  No clinically significant differences in the clinical efficacy, safety, pharmacokinetic, or pharmacodynamic were observed in the patients who tested positive for ADA.</p><p><b>Uncommon</b> (0.1% to 1%): Treatment emergent anti-drug antibodies</p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (10%)</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Givlaari (givosiran)." Alnylam Pharmaceuticals, Cambridge, MA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about givosiran</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous metabolic agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Givosiran Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Givlaari</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Porphyria</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to givosiran: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions included nausea and injection site reactions.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylactic reaction, hypersensitivity</p><p>In clinical trials, 1 patient experienced an anaphylactic reaction and 1 patient experienced a hypersensitivity reaction.</p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Transaminase elevations (13%)</p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increase serum creatinine (15%; includes blood creatinine increased, glomerular filtration rate decreased, chronic kidney disease [decreased eGFR])</p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site reactions (25%)</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (27%)</p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (17%; includes pruritus, eczema, erythema, rash, pruritic rash, urticaria)</p><h3>Immunologic</h3><p>As with all oligonucleotides, there is a potential for immunogenicity.  The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay and therefore comparison of antibody incidence is misleading.  In placebo-controlled and open-label clinical studies, 1 of 111 patients with acute hepatic porphyria (AHP;0.9%) developed treatment-emergent anti-drug antibodies (ADA) during treatment.  No clinically significant differences in the clinical efficacy, safety, pharmacokinetic, or pharmacodynamic were observed in the patients who tested positive for ADA.</p><p><b>Uncommon</b> (0.1% to 1%): Treatment emergent anti-drug antibodies</p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (10%)</p><p id="ref_1">1. "Product Information. Givlaari (givosiran)." Alnylam Pharmaceuticals, Cambridge, MA. </p><h2>More about givosiran</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous metabolic agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Givosiran Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Porphyria</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>